Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Parkin (PARK2, Parkinson disease protein 2) (C-Term) antibody
Alternatives Immunohistochemistry (IHC), Western Blotting (WB)
|5 references available|
|Quantity||150 µl (Variants)|
|Price||454.67 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 7 to 8 Business Days|
|Immunogen||A synthetic peptide from the c-terminal of Parkin (PARK2, Parkinson disease protein 2) conjugated to an immunogenic carrier protein was used as the immunogen. The antigen is homologous in rat and shares 95% identity with mouse sequence.|
|Description||Function: Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP and SEPT5. May play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin E during neuronal apoptosis. May represent a tumor suppressor gene. Subcellular location: Cytoplasm. Nucleus. Note: Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. Tissue specificity: Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis. Also known as: AR JP, E3 ubiquitin protein ligase parkin, FRA6E, LPRS 2, LPRS2, PARK 2, PARK2, Parkinson disease (autosomal recessive juvenile) 2, Parkinson disease protein 2, Parkinson juvenile disease protein 2, PDJ, PRKN 2, PRKN, PRKN2, Ubiquitin E3 ligase PRKN.|
|Specificity||Appears to be specific for Parkin.|
|Application Notes||IHC, WB. A dilution of 1: 300 to 1 : 2000 is recommended. The optimal dilution should be determined by the end user. Not yet tested in other applications.|
|Storage||Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.|
|Restrictions||For Research Use only|
Kitada, Asakawa, Hattori et al.: "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism." in: Nature, Vol. 392, Issue 6676, pp. 605-8, 1998 (PubMed).
Shimura, Hattori, Kubo et al.: "Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients." in: Annals of neurology, Vol. 45, Issue 5, pp. 668-72, 1999 (PubMed).
Shimura, Hattori, Kubo et al.: "Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase." in: Nature genetics, Vol. 25, Issue 3, pp. 302-5, 2000 (PubMed).
Imai, Soda, Takahashi: "Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity." in: The Journal of biological chemistry, Vol. 275, Issue 46, pp. 35661-4, 2000 (PubMed).
Mungall, Palmer, Sims et al.: "The DNA sequence and analysis of human chromosome 6." in: Nature, Vol. 425, Issue 6960, pp. 805-11, 2003 (PubMed).
|Applications||Immunohistochemistry (IHC) (1), Western Blotting (WB) (1)|